secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vicapsys Life Sciences, Inc. (VICP)
CIK:        0001468639
Form:       8-K
Filed at:   2022-04-12T23:59:59+00:00
Accession:  0001493152-22-009690
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vicapsys Life Sciences appoints Federico Pier as CEO, effective Feb 15, 2022
----------------------------------------------------------------------------

- Federico Pier appointed CEO effective Feb 15, 2022; previously interim CEO since Aug 2020 and Executive Chairman since May 2019.
- Pier has 25+ years of experience in reverse mergers, structured finance, convertible debt, and equity; past roles at Oppenheimer & Co. and Bear Stearns.
- Company develops VICAPSYN for transplantation and VYBRIN for post-surgical adhesions; trades OTC under symbol VICP.
- The appointment was announced via press release dated April 12, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468639/000149315222009690/0001493152-22-009690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468639/000149315222009690/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-009690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer